Osiris Therapeutics, Inc. (NASDAQ:OSIR)

CAPS Rating: 1 out of 5

A stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas.

Results 1 - 20 of 35 : 1 2 Next »

Recs

0
Member Avatar tftarpey (< 20) Submitted: 2/11/2015 8:49:41 PM : Outperform Start Price: $14.84 OSIR Score: -61.45

This stock has the rare combination of elements that spell winner with a capital W : Cash flow,Management,Pipe line and Top science. These gentlemen and women have a record second to none in the stem cell field. Do the DD yourself. 52% insider ownership and a very small float.Earns tomorrow, log on and listen to the shorts scream !

Recs

0
Member Avatar manirg (< 20) Submitted: 8/16/2013 7:11:40 PM : Outperform Start Price: $18.94 OSIR Score: -94.95

high growth ahead

Recs

0
Member Avatar TMFBiologyFool (91.92) Submitted: 6/22/2012 6:20:49 PM : Underperform Start Price: $12.06 OSIR Score: +109.75

May not be the top, but all unjustified runs come to an end.

Recs

0
Member Avatar Eversar (93.88) Submitted: 3/3/2010 5:13:18 PM : Outperform Start Price: $7.47 OSIR Score: -108.38

Unusually high call volume at $10 for 3/10

Recs

0
Member Avatar minifesto (66.33) Submitted: 10/27/2009 2:24:59 PM : Outperform Start Price: $6.41 OSIR Score: -105.90

Stem cell company with partnership with Genzyme. Market value $220 million with cash $130 million. Percieved failure lead product trial tanked stock.

Recs

0
Member Avatar riegonla (41.94) Submitted: 10/15/2009 1:43:04 AM : Outperform Start Price: $6.85 OSIR Score: -107.74

14 US$ 1 Nov 2009

Recs

0
Member Avatar Jmachine (< 20) Submitted: 9/14/2009 1:08:14 PM : Outperform Start Price: $7.78 OSIR Score: -126.01

I say it's time to get in on this stock.

Recs

0
Member Avatar Broken196 (< 20) Submitted: 9/9/2009 11:32:25 AM : Underperform Start Price: $7.63 OSIR Score: +126.03

So much money lost on their failed drug.

Recs

0
Member Avatar sfmain (< 20) Submitted: 9/2/2009 9:41:53 AM : Outperform Start Price: $14.29 OSIR Score: -168.06

super option yields and a firm 10.00 bottom

Recs

0
Member Avatar DTMINC (< 20) Submitted: 8/26/2009 2:16:54 PM : Outperform Start Price: $14.25 OSIR Score: -161.69

New approval for phase III drug next week.

Recs

0
Member Avatar Brian7992 (67.19) Submitted: 8/20/2009 7:40:30 AM : Outperform Start Price: $11.56 OSIR Score: -158.60

Best Bio Bets

Recs

0
Member Avatar SteveTheBluesman (92.64) Submitted: 3/16/2009 9:46:58 AM : Outperform Start Price: $17.83 OSIR Score: -241.92

The only stem company that makes money. Huge deal with Genzyme. They are ready to double.

Recs

0
Member Avatar supernaut2009 (< 20) Submitted: 2/18/2009 11:34:10 PM : Outperform Start Price: $19.76 OSIR Score: -234.61

With the Democrats in, this industry will receive a boost. I was "foolish" enough to sell this stock after a quick bounce shortly after its IPO. I am still a bit timid with this sector and its corresponding volatility...

Recs

0
Member Avatar JD2840 (< 20) Submitted: 1/23/2009 2:12:15 PM : Outperform Start Price: $19.69 OSIR Score: -223.29

Phase II data was exceptional.

This 'drug' (really cells) are the last in a line of options for patients dying of GVHD. If you don't know what GVHD is, you shouldn't rate this stock. The safety data thus far are exceptional, and if they have a little efficacy (and it looks like they have a lot), this will be a

This will be approved, and the use of the drug expanded rapidly.

At 15K per treatment (my numbers), they need a base of about 3500 patients to be a 500 million revenue.. should value at 5 bill or a 10 bagger...

Good luck

Recs

0
Member Avatar cyborsurfer (< 20) Submitted: 11/4/2008 7:34:22 PM : Outperform Start Price: $16.83 OSIR Score: -180.00

Stock that has beat the S&P 500 most of 2008 and insiders own more than 10 percent of the stock.

Recs

1
Member Avatar Aarin7 (< 20) Submitted: 7/31/2008 1:01:02 PM : Underperform Start Price: $15.81 OSIR Score: +131.34

At $16, this stock is over priced. It has a lot of future potential but has very little profits to speak of. Their trials in adult stem research have shown major break troughs but are expensive. This stock should bloom with a more liberal president in office. In the short term, the stock is a $12-13 stock. In the long term, this stock will eventual explode IF they do not use all of their capital before FDA approval.

Recs

1
Member Avatar riskybus (< 20) Submitted: 7/8/2008 12:14:29 AM : Outperform Start Price: $13.88 OSIR Score: -129.92

"Osiris was the God who made the seeds ripe for the harvesting, and also could raise those from the dead."

Recs

1
Member Avatar eyunker (95.89) Submitted: 5/10/2008 1:07:26 AM : Outperform Start Price: $12.60 OSIR Score: -109.13

Osiris currently has some very promising stem cell treatments in the works including Prochymal, which could change the way diseases such as GVHD and Crohns are treated. They have some promising government contracts and Prochymal has been fast tracked by the FDA. I think this stock will take off starting in mid to late 2009.

Recs

0
Member Avatar edwardgs (32.26) Submitted: 4/23/2008 11:41:20 PM : Outperform Start Price: $11.61 OSIR Score: -107.80

medical

Recs

1
Member Avatar xfool4me (< 20) Submitted: 4/1/2008 8:16:54 PM : Outperform Start Price: $12.53 OSIR Score: -111.10

Burning cash like a rocket burning fuel at takeoff, Osiris is developing unique and much needed products. It may be several years before this stock takes off in the direction of ISRG but if they are successful in product development the potential is here. I believe adult stem cell research and development is the only ethical stem cell path and have put my money where my heart is!

Results 1 - 20 of 35 : 1 2 Next »

Featured Broker Partners